Emergent Biosolutions
EBS
169 hedge funds and large institutions have $352M invested in Emergent Biosolutions in 2025 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 48 increasing their positions, 54 reducing their positions, and 29 closing their positions.
253% more call options, than puts
Call options by funds: $8.26M | Put options by funds: $2.34M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
46% more capital invested
Capital invested by funds: $241M → $352M (+$112M)
28% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 29
5.09% more ownership
Funds ownership: 73.07% → 78.16% (+5.1%)
5% more funds holding
Funds holding: 161 → 169 (+8)
11% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$5.48M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$4.56M |
| 3 |
JG
Jain Global
New York
|
+$3.96M |
| 4 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$2.54M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.27M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.97M |
| 3 |
Two Sigma Advisers
New York
|
-$1.87M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.71M |
| 5 |
Morgan Stanley
New York
|
-$1.59M |
EBS Hedge Fund Activity: Q3 2025 in Review
169 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2025, worth a combined $352M — up 46% from $241M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new EBS positions and 29 closed out — a net gain of 8 holders — while 48 added to existing stakes and 54 trimmed.
The largest buyer was State Street, adding an estimated $5.48M. The largest seller was Millennium Management, cutting an estimated $5.27M.
- 169 institutional investors held Emergent Biosolutions (EBS) as of Q3 2025, up from 161 in Q2 2025.
- Funds reported $352M of Emergent Biosolutions stock for Q3 2025, up 46% quarter-over-quarter.
- 37 funds opened new Emergent Biosolutions positions in Q3 2025 and 29 closed out, a net change of +8 holders.
- The largest Emergent Biosolutions buyer in Q3 2025 was State Street, an estimated $5.48M added.
- The largest Emergent Biosolutions seller in Q3 2025 was Millennium Management, an estimated $5.27M sold.
Based on aggregated 13F filings for Q3 2025.